Ocuphire Pharma Signs an Exclusive License Agreement with FamyGen for Nyxol Eye Drops to Treat Reversal of Mydriasis, Presbyopia and Night Vision Disturbances
- Ocuphire will receive $35M up front, $10M milestones upon FDA approval & is eligible to receive additional regulatory & sales milestones along with royalties. The companies collaborated for Nyxol across 3 indications in the US, EU, Japan, India, China & other markets globally
- Famy will be responsible to fund & commercialize the development of Nyxol eye drops in the US incl. clinical, manufacturing & regulatory activities required for FDA approval of all 3 Nyxol indications, incl. Nyxol+Low-Dose Pilocarpine
- The activities will be managed by Ocuphire. Famy will lead the development in non-US markets. Nyxol is currently being studied in the P-III trial for presbyopia and NVD while NDA submission for RM is expected in Q4’22
Ref: Globenewswire | Image: Ocuphire
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.